Coronavirus channel feed

As­traZeneca's vac­cine hit its first road­block with In­di­an reg­u­la­tors. Will lin­ger­ing doubts de­rail its plans else­where?

5 years ago
FDA+

Covid-19 roundup: UAE claims Sinopharm vac­cine 86% ef­fec­tive, but de­tails are scant; In­dia re­port­ed­ly re­jects As­traZeneca's vac­cine, while UK con­ducts 'all en­com­pass­ing' re­view 

5 years ago

As­traZeneca pub­lish­es in­ter­im vac­cine da­ta in Lancet, re­veals 10 hos­pi­tal­iza­tions, 1 death in piv­otal con­trol arms

5 years ago
FDA+

FDA in­ter­nal re­view points to im­mi­nent Pfiz­er/BioN­Tech EUA, spot­lights po­ten­tial for sin­gle-dose vac­ci­na­tion

5 years ago
FDA+

Dri­ven by Covid-19 fever, For­bion notes in­vestor in­ter­est in vac­cines and new ther­a­pies as part of $557M fund

5 years ago
Financing

Covid-19 roundup: Pfiz­er and Mod­er­na won't at­tend White House­'s 'Vac­cine Sum­mit' — re­port; Sino­vac clar­i­fies ef­fi­ca­cy num­bers

5 years ago

Seat­tle's AGC plots $194M in­vest­ment to dou­ble pro­duc­tion at Copen­hagen site in busy year for bi­o­log­ics

5 years ago
Outsourcing
Pharma

Covid-19 roundup: In­dia moves for­ward with re­view of Pfiz­er and As­traZeneca vac­cine can­di­dates; Chi­na's Sino­vac gets $515M to dou­ble vac­cine pro­duc­tion

5 years ago

Lil­ly part­ners with Unit­ed­Health to con­duct 're­al-world' study for its Covid-19 an­ti­body bam­lanivimab

5 years ago

Covid-19 roundup: Mod­er­na of­fers glimpse at dura­bil­i­ty da­ta; Bribery scan­dals mar Sino­vac's rep­u­ta­tion

5 years ago

As UK awaits first Covid-19 vac­cine dos­es, Fau­ci and oth­ers crit­i­cize its 'hasty' de­ci­sion

5 years ago

This is how Bern­stein divvies up a $40B Covid-19 vac­cine mar­ket among the lead­ers in the race to an ap­proval

5 years ago

Covid-19 roundup: In­ovio en­lists plas­mid man­u­fac­tur­er to re­place the one it's in le­gal feud with; Cy­ber­at­tacks spot­ted tar­get­ing vac­cine dis­tri­b­u­tion 

5 years ago

Covid-19 roundup: CDC votes on who should get vac­cines first; As­traZeneca's In­di­an part­ner won't switch dos­ing reg­i­mens

5 years ago

UK grants Pfiz­er, BioN­Tech his­toric first OK for mR­NA vac­cine, ex­pects mil­lions of dos­es by year end

5 years ago
FDA+

Af­ter Mod­er­na and Pfiz­er's stel­lar re­sults, the come­back play­ers at No­vavax face big ques­tions about their best-in-class hunt in a fren­zied Covid-19 vac­cine race

5 years ago
R&D

Covid-19 roundup: Pfiz­er and Mod­er­na take their vac­cines to the EMA; Chief of Staff Mark Mead­ows calls Hahn to White House — re­port

5 years ago

Re­gen­eron teams with gene ther­a­py pi­o­neer James Wil­son, adapt­ing its Covid-19 an­ti­body cock­tail to an AAV-based nasal spray

5 years ago
Deals

Covid-19 roundup: No­vavax de­lays US, Mex­i­co vac­cine tri­al (again); In­dia in­ves­ti­gates re­port­ed side ef­fects in As­traZeneca study

5 years ago

As­traZeneca CEO So­ri­ot plans new study to test that con­tro­ver­sial 90% ef­fi­ca­cy fig­ure, wait­ing for US da­ta be­fore go­ing to FDA

5 years ago

Mod­er­na cal­i­brates fi­nal Covid-19 vac­cine ef­fi­ca­cy at 94.1% — and to­day it's gun­ning for the EUA

5 years ago
R&D

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

5 years ago
Outsourcing

FDA hands Liq­uidia and Re­vance a CRL and de­fer­ral, re­spec­tive­ly, as Covid-19 cre­ates in­spec­tion chal­lenge

5 years ago
FDA+

Covid-19 roundup: Eu­rope pur­chas­es 80M dos­es of Mod­er­na's vac­cine; CO­V­AXX se­cures $2.8B in emerg­ing mar­ket pre-or­ders

5 years ago
First page Previous page 37383940414243 Next page Last page
A service from the Financial Times